QuartzBio has secured a strategic investment and majority ownership from private equity company Eir Partners to expedite its clinical trial intelligence platform.
The move marks a significant step as QuartzBio strengthens its role as a foundation for biopharma companies focused on optimising operational efficiency and enhancing data control in clinical trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
QuartzBio’s vendor‑agnostic, AI‑based platform is designed to address challenges in clinical development operations.
It unifies chain of custody, sample collection, metadata integrity, consent status, and biomarker results, providing real-time oversight and control across entire clinical trial portfolios.
The investment enables QuartzBio to fast-track improvements across its platform and operational model.
The company will focus on expanding interoperability at the portfolio scale, allowing seamless integration across contract research organisations (CROs), laboratories, and clinical systems.
It will also deepen the AI-driven automation used for workflow management, risk identification, and ensuring data completeness.
QuartzBio is set to provide more advanced analytics and benchmarking, enabling multi-trial decision-making for clients, and will further increase enterprise scalability, security, and compliance with global standards.
The company will also expand its customer support and implementation capacity to keep pace with the rising adoption of its technology.
QuartzBio CEO Scott Marshall said: “Modern clinical development generates unprecedented volumes of data, yet trial risk persists because that data is fragmented, delayed, or unreliable.
“This investment allows us to double down on delivering a scalable software platform that removes manual oversight, protects scientific integrity, and materially reduces trial cost and duration.”
Eir Partners founder and CEO Brett Carlson said: “AI is fundamentally transforming clinical development, and sample and biomarker intelligence represents one of its highest-impact applications.
“QuartzBio has demonstrated both strong product market fit and tangible economic impact for sponsors managing complex portfolios. By embedding domain-specific AI directly into clinical and translational workflows, the company is well positioned to shape how next-generation trials are conducted.”
The terms of the transaction remain undisclosed. Bourne Partners served as QuartzBio’s exclusive financial adviser for this transaction.
